Empowering manufacturing decisions through process simulation models by Rau, Tiffany et al.
Engineering Conferences International
ECI Digital Archives
Cell Culture Engineering XVI Proceedings
5-6-2018
Empowering manufacturing decisions through
process simulation models
Tiffany Rau
BioProcess Technology Consultants, USA, trau@bptc.com
Terence Davidovits
BioProcess Technology Consultants, USA
Rick Stock
BioProcess Technology Consultants, USA
Follow this and additional works at: http://dc.engconfintl.org/ccexvi
Part of the Engineering Commons
This Abstract and Presentation is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion
in Cell Culture Engineering XVI by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.
Recommended Citation
Tiffany Rau, Terence Davidovits, and Rick Stock, "Empowering manufacturing decisions through process simulation models" in "Cell
Culture Engineering XVI", A. Robinson, PhD, Tulane University R. Venkat, PhD, MedImmune E. Schaefer, ScD, J&J Janssen Eds, ECI
Symposium Series, (2018). http://dc.engconfintl.org/ccexvi/173
Empowering Manufacturing Decisions through 
Process Simulation Models
Tiffany D. Rau, PhD* and Rick Stock, PhD
BioProcess Technology Consultants 







Bioprocessing using stainless steel equipment has been used for decades. Many of the top-selling monoclonal antibodies are manufactured in stainless steel systems. The 
single-use systems are being adopted in small to medium scale process and especially in process development. Even recently installed large scale manufacturing 
operations have installed a considerable number of single-use systems in media & buffer prep and seed train areas. This is not particularly revealing as we can see in this 
study, that single-use technologies can realize cost savings over stainless steel. But in some cases such as scaling-out there is no savings over the efficiencies of scale. It is 
also apparent through modeling scenarios that single-use systems bring a level of flexibility that is difficult to quantify but favorable for adapting to manufacturing 
changes. Another use of modeling COGS demonstrated was to use the cost results to develop a manufacturing strategy taking into account the risks associated with 
producing a product by building your own plant or by outsourcing each batch or renting a suite from a CMO. Process Economic Modeling is a tool that lends itself to not 
only complex processes but also platform processes as organizations are deciding how and where to manufacture products now and in the future.
Conclusion
Introduction
➢ Process economic modeling using commercial software or in-house custom models can 
be used to meet a variety of objectives and improve decision making:
• Estimate COGS at production scale for products in development
• Evaluate economic feasibility of processes/products
• Estimate operational and capital costs for manufacturing facilities
• Quantify the impact of new technologies or process changes on COGS
• Support negotiations with contract manufacturers
• Optimize global supply chain strategies
➢ Examples of cost modeling tools
• Custom models (typically MS Excel-based)
• BioSolve (BioPharm Services, Chesham, UK)
• SuperPro Designer (Intelligen, Scotch Plains, NJ)
Why Develop Process Economic Models?
Methods
Models were created using either BioSolve Process v7.5 (Biopharm Services Limited) and/or 
SuperPro Designer (Intelligen Inc.) to explore COGs & net present value (NPV). 
• Scaling up versus scaling out model uses BioSolve Process v7.5 to explore and compare 
cost of goods for a 12,000 L Stainless Mab Facility compare to 6x 2,000L Single-Use Facility 
manufacturing 3 Mabs per year at commercial scale. 
• Flexibility of the Manufacturing Process Single-Use (SU) versus Stainless Steel (SS) model 
uses BioSolve Process v7.5 to conduct a COGs comparison of a 2,000 L SS facility 
compared to a 2,000L Single-Use Facility which illustrates the value of flexibility.
• NPV Analysis to Determine Best Option: Buy, Rent or Build model uses BioSolve Process 
v7.5 to conduct net present value (NPV) analysis to evaluate options such as batch 
outsourcing to a CMO, renting suite space from a CMO, or building a facility for a ,000L 
Single-Use Bioreactor facility
• A complex 6 valent conjugate vaccine was modeled in SuperPro Designer (Intelligen Inc.) 
to demonstrate the powerful scheduling and complexity of campaigning of multiple drug 
substances in the same production equipment.
Introduction
The biopharmaceutical industry continues to face increasing pressure to reduce overall costs 
of life improving and saving treatments. The clinical and commercial stages of the drug 
development life cycle are areas where reduced costs may be realized. This poster focuses 
on one area were cost savings may be realized which is in the clinical and commercial stages 
of the drug development lifecycle. Having tools to assist in the evaluation of new 
technologies, single-use options and impact of process changes on cost of goods (COGS) can 
be critical to predictive and robust cost saving strategies. In addition to predicting COGS it is 
necessary to determine the facility where the product should be produced whether that is a 
best fit for products in existing facilities versus building new facilities versus outsourcing to a 
contract manufacturing organization (CMO). The aim of this study is to demonstrate how to 
use COGS studies to make informed strategic manufacturing decisions to understand the 
manufacturing financial risks and ultimately save on production costs.
BPTC’s Standard 2,000L SU Mab Model
High Level Assumptions: 2,000L Stainless Steel Batch & 2,000L Single-Use Batch
Key Common Between 2,000L Batch SS & 2,000L SU
➢Titer:  2 g/L; Downstream yield: 70%, 
➢Production cell culture time: 12 days; Batches per Year:  20
➢Capital assumptions: cost of capital = 8%, 10 year depreciation and 5% salvage value
➢5% batch failure rate, 90% Utilization of available manufacturing capacity
Key Different Assumptions Between 2,000L SS Batch and 2,000L SU Batch:
➢Capital costs:  2,000L SS – $25.8M, 2,000L SU – $22.7M
➢Changeovers: 2,000L SS – 0 (no changeovers), 2,000L SU – 2 changeovers for 3 different 
Mab products
➢Total Changeover Time:  2,000L SS – 0 days, 2,000L SU – 6 days 
➢Downtime for maintenance and validation: 2,000L SS – 6 wks, 2,000L SU – 4 wks
➢
In this example both facilities are producing 20 batches/year but the single-use facility 
changeovers are more efficient thus three different Mabs may be produced in the same 
facility in a given year. The COGS are more favorable for the single-use facility and the 
flexibility to adapt to product demand shifts is difficult to quantify but certainly desirable. If 
the stainless-steel facility scenario changed requiring product change-overs the change-over 
efficiency would decrease and COGS would increase.
Manufacturing Flexibility: SU vs. SS
➢ Fixed: Costs that will not change as the amount of product being made increases 
or decreases
• Facility capital and Equipment capital
➢ Variable: Costs that directly scale with the number of batches
• Raw materials, Single use consumables, and waste
➢ Semi-variable: Cost that can increase/decrease with production but not directly
▪ Direct labor and overhead
Different Types of Cost














Can be custom designed to look at a 
variety of sensitivities/parameters
Conclusions
• Overall commercial production assumptions:
• Production scale: 2,000L SUB
• Drug product doses per batch: 2,875
• Max batches/year: 20
• Commercial validation costs: $1,500,00
• Commercial production begins in 2021
• Materials & consumables cost/batch $40,000
• Drug product filling cost/batch: $150,000
• NPV discount rate 12%
• #Patients: Year 1: 1200, Year 2: 2600, Year 3+:7,150
• Doses/patient/year: 8
• Sales price $800/dose
• CMO buy option assumptions:
• $750,000 batch cost (<5 batches, materials incl.)
• $670,000 batch cost (>15 batches ,materials incl.)
• Overhead (oversight)/batch cost $15,000
• CMO rent option assumptions:
• Upfront reservation payment: $7M
• Annual suite cost: $8M (labor incl., no materials)
• Each suite can run 20 batches/year
• Overhead (oversight)/batch cost $15,000
• Build facility option
• Installed capital: $25.1M, 10 year depreciation
• Annual labor: $3.1M
• Annual facility overhead $900,000
Overview:
This example investigates the “best” path to commercialization over 6 years of 
product sales. Three options are available: outsource each required batch to a CMO, 
secure and rent suites from a CMO or build a greenfield facility for commercial 
production. Each CMO option will require costs associated with oversight of the 
commercial production, tech transfer and validation of the process. Outsourcing to a 
CMO has the least cash risk but is costly having the lowest Net Present Value (NPV). 
The outsourcing scenario could have risks associated with the availability of CMO 
capacity. This is a driver for a rental option. This option requires an upfront payment 
per suite rental but secures capacity at a lower price per batch. Properly utilizing the 
suite capacity for commercial production makes the rent option better than 
outsourcing on a batch by batch basis. There is often a large cash risk associated with 
the rent option because the payment is often secured before the product is approved 
for commercial launch. The build option is always the best option when the facility is 
fully utilized. However, this option is also the highest risk option since all of the capital 
to build the facility must be spent before commercial production can begin.
NPV Analysis: Buy, Rent, Build
High Level Assumptions: 12,000L SS Batch & 6 x 2,000L SU Batch
Key Common Between 12,000L SS Batch & 6 x 2,000L SU Batch
• Titer:  2 g/L; Downstream yield:  70%; Production cell culture time:  12 days
• 2 Changeovers for 3 different Mab products
• Capital assumptions: cost of capital = 8%, 10 yr depreciation, 5% salvage value
• 5% batch failure rate, 90% Utilization of available manufacturing capacity
Key Different Assumptions Between 12,000L SS Batch and 6 x 2,000L SU Batch:
• Capital costs:  12,000L SS – $51.2M, 6 x 2,000L SU – $38.0M
• Batches per Year:  12,000L SS – 19 batches, 6 x 2,000L SU – 21 equivalent batches 
(126 batches)
• Total Changeover Time:  12,000L SS – 20 days, 6 x 2,000L SU – 6 days 
• Downtime- maintenance & validation: 12,000L SS – 6 wk, 6 x 2,000L SU - 4 wk
Scaling Up Versus Scaling Out
Model Overview:
In this example we compare the costs involved with operating a 12,000L stainless steel 
facility to a 6 x 2,000L scaled out facility. The facilities were each designed to handle 
production of 3 different products in campaign mode. Since the 6 x 2,000L single-use 
bioreactor facility could be turned around quicker between batches and changeovers, it has 
a higher throughput of 21 equivalent 12,000L batches per year compared to 19 batches per 
year. There is a considerable amount of labor needed to run 6 x 2,000L for 126 batches 
which dominates the COGS. While there are savings in capital costs and waste by scaling out 
at the 2,000L scale the costs in consumables and materials also increase compared to the 
12,000L bioreactor. Overall the total cost per gram nearly doubles by scaling the process 
out. In certain scenarios scaling out may be beneficial such as when demand forecasts are 
lower than expected and slowly adding 2,000L bioreactors meets demand more evenly than 
a single under-utilized 12,000L bioreactor.
CMO vs. Risk of Under Utilizing Capacity 
This example looks at the break even point 
between out-sourcing batches to a CMO 
versus building a greenfield facility. The bar 
graph represent the batch cost as the number 
of batches/year increase. A single batch in a 
greenfield facility is very expensive and the 
price drops as the capital and labor are fully 
utilized. The CMO marked up batch price does
not change much even if more batches are produced. It is assumed that the CMO will fill 
unused capacity. In this case 12 batches is the break even point between building a new 
facility and outsourcing manufacturing to a CMO.
Model Complex Production Processes
The process depicted is for producing 
six different polysaccharide serotypes 
(Fermentation A line) that are each 
conjugated to an antigen from 
(Fermentation B line). The 
formulation, fill and finish (FFF) line is 
also shown but for simplicity only one 
conjugate serotype is shown entering 
the FFF line. This manufacturing 
strategy is very complex and not easy to model in a spreadsheet like Excel. SuperPro 
Designer allows the process to be set up and alerts the user when equipment scheduling 
conflicts occur ensuring success in meeting product demand.
